Albert Villafania
Primary Care · Phoenix, AZNPI 1174305700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 422 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,601, more than ten times the $40 reported in 2023. Among primary care clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1K
- AbbVie$998
- Axsome Therapeutics, Inc.$855
- Harmony Biosciences LLC$646
- Pfizer$514
- Avadel CNS Pharmaceuticals, LLC$396
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,12393%
- Education$5127%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 31 | $1,130 |
| AbbVie | 78 | $998 |
| Axsome Therapeutics, Inc. | 47 | $855 |
| Harmony Biosciences LLC | 30 | $646 |
| Pfizer | 31 | $514 |
| Avadel CNS Pharmaceuticals, LLC | 16 | $396 |
| UCB, Inc. | 24 | $303 |
| AstraZeneca | 7 | $299 |
| Lilly USA, LLC | 16 | $255 |
| Teva Pharmaceuticals USA, Inc. | 15 | $248 |
| Inspire Medical Systems, Inc. | 25 | $232 |
| Biogen | 14 | $202 |
| ZOLL Respicardia, Inc. | 14 | $195 |
| Amneal Pharmaceuticals LLC | 10 | $181 |
| Genentech USA, Inc. | 7 | $177 |
| Argenx US, Inc. | 14 | $162 |
| Lundbeck LLC | 6 | $139 |
| Novartis | 6 | $115 |
| Eisai Inc. | 6 | $112 |
| SK Life Science, Inc. | 3 | $95 |
| Bristol Myers Squibb | 5 | $82 |
| GE HealthCare | 3 | $65 |
| Neurelis, Inc. | 3 | $53 |
| Impel Pharmaceuticals LLC | 3 | $52 |
| Tanabe Pharma America, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Organon | 1 | $17 |
| Catalyst Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| 3b Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,636 in reported general payments places this provider in the 95th percentile of 151 primary care providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SunosiSolriamfetol Hcl | 22 | $16,025 |
| DayvigoLemborexant | 32 | $13,043 |
| Lacosamide | 23 | $2,212 |
| Pregabalin | 68 | $1,309 |
| Modafinil | 19 | $803 |
| Quetiapine Fumarate | 26 | $639 |
| Gabapentin | 52 | $609 |
| Donepezil Hcl | 32 | $389 |
| Eszopiclone | 40 | $353 |
| Mirtazapine | 37 | $312 |
| Clonazepam | 33 | $305 |
| Memantine Hcl | 14 | $292 |
| Lamotrigine | 11 | $247 |
| Primidone | 15 | $220 |
| Promethazine Hcl | 12 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Sunosi | $855 | $16,02522 claims |
| Eisai Inc.Dayvigo | $112 | $13,04332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 151 primary care providers in Arizona.
Other primary care in Phoenix
- Trey PowrzanasPhoenix$16K
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Charity CorreaPhoenix$5K
- Cara Loveless-FaulknerPhoenix$4K
- Chelsea GreenwoodPhoenix$4K
- Kerry OliverPhoenix$2K
- Kathryn SuessPhoenix$2K
- Nahla ChircoPhoenix$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.